ORPHA:258
Laminin subunit alpha 2-related congenital muscular dystrophy
Also known as: CMD1A · Congenital muscular dystrophy due to laminin alpha2 deficiency · Congenital muscular dystrophy type 1A · MDC1A · Merosin-negative congenital muscular dystrophy
Publications
11,075
94.7th percentile
Trials
0
Interventional, condition-specific
Researchers
1,177
Distinct authors in sample
Gene link
LAMA2
Definitive
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare muscular characterized by severe , muscle weakness and muscle wasting presenting at birth or during infancy, poor spontaneous movements and contractures of the large joints. Patients have poor motor development leading to feeding and respiratory issues.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011925
- OMIM:607855
- UMLS:C1263858
- NCIT:C118783
Additional Mondo synonyms (8)
LAMA2 congenital muscular dystrophy · congenital merosin-deficient muscular dystrophy type 1A · congenital muscular dystrophy caused by mutation in LAMA2 · congenital muscular dystrophy due to laminin alpha2 deficiency · merosin-deficient congenital muscular dystrophy type 1A · merosin-negative congenital muscular dystrophy · muscular dystrophy, congenital merosin-deficient, type 1A · muscular dystrophy, congenital, merosin deficient or partially deficient
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — LAMA2
- LiteraturePresent
11,075 matched papers (5,195 in last 10 years) Source
- Phenotype characterisedPresent
70 HPO annotations (e.g. Ophthalmoplegia; Muscular dystrophy; Feeding difficulties in infancy) Source
- Animal modelPresent
18 genotype models (Mus musculus, Danio rerio) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 7 for broader category congenital muscular dystrophy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (LAMA2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
70
Associated phenotypes · MONDO:0011925
- Ophthalmoplegia
- Muscular dystrophy
- Feeding difficulties in infancy
- Muscle weakness
- Flexion contracture
Showing 5 of 70 — open Monarch for the full list.
Animal models (Monarch / Alliance)
18
Model associations linked to this Mondo ID
- Lama2dy-2J/Lama2dy-2J [background:] B6.WK-Lama2dy-2J·MGI:3789335·Mus musculus
- lama2teg15a/teg15a·ZFIN:ZDB-FISH-150901-12102·Danio rerio
- lama2cl501/cl501·ZFIN:ZDB-FISH-170615-2·Danio rerio
- lama2cl501/cl501 (AB)·ZFIN:ZDB-FISH-150901-15844·Danio rerio
- lama2tk209/tk209·ZFIN:ZDB-FISH-150901-22094·Danio rerio
- Lama2tm1Eeng/Lama2tm1Eeng [background:] involves: 129S1/Sv * Black Swiss * FVB/N·MGI:3522485·Mus musculus
- Lama2tm1Eeng/Lama2tm1Eeng [background:] involves: 129S1/Sv·MGI:4947712·Mus musculus
- Lama2tm1Eeng/Lama2tm1Eeng [background:] involves: 129S1/Sv * Black Swiss·MGI:3522483·Mus musculus
- Lama2dy-8J/Lama2dy-8J [background:] C57BL/6J-Lama2dy-8J/GrsrJ·MGI:3848948·Mus musculus
- Lama2dy/Lama2dy [background:] involves: 129P1/Re·MGI:3783638·Mus musculus
- Lama2dy-Pas/Lama2dy-Pas [background:] involves: non-inbred stock·MGI:6226150·Mus musculus
- Lama2dy-7J/Lama2dy-7J [background:] C57BL/6J-Lama2dy-7J/J·MGI:3581453·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
11,075
11,075 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
11,075 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
5,195 in the last 10 years · high confidence · 94.7th percentile (publications denominator)
Phrase hits: 7,651 · MeSH hits: 0
Who's working on it?
1,177
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Burkin DJ8 papers · 2023
Department of Pharmacology, Reno School of Medicine, University of Nevada, Reno, NV, United States.
Papers in Europe PMC - 02Yokota T8 papers · 2025
Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, Edmonton Canada.
Papers in Europe PMC - 03Durbeej M7 papers · 2025
Muscle Biology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden. Electronic address: madeleine.durbeej-hjalt@med.lu.se.
Papers in Europe PMC - 04Cohn RD5 papers · 2023
Program in Genetics and Genome Biology, The Hospital for Sick Children Research Institute, Toronto, Canada.
Papers in Europe PMC - 05Kemaladewi DU5 papers · 2025
Program in Genetics and Genome Biology, The Hospital for Sick Children Research Institute, Toronto, Canada.
Papers in Europe PMC - 06Thorsteinsdóttir S5 papers · 2024
Departamento de Biologia Animal, Centro de Ecologia, Evolução e Alterações Ambientais, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisbon, Portugal.
Papers in Europe PMC - 07Voermans NC5 papers · 2024
From the Department of Neurology (K.B., J.D., N.A., B.G.M.E., N.C.V.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Neurology (K.B., C.E.E.), Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital; Department of Rehabilitation (J.T.G.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Cardiology (F.E.A.U.C.), Amalia Children's Hospital; Department of Cardiology (F.M.A.H., R.N.); Department of Human Genetics (E.-J.K.); Department of Pediatrics (A.T.M.D., J.M.T.D.), Radboud Institute for Health Sciences, Amalia Children's Hospital; and Department of Internal Medicine (M.C.H.J.), Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC - 08Bouman K4 papers · 2024
From the Department of Neurology (K.B., J.D., N.A., B.G.M.E., N.C.V.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Neurology (K.B., C.E.E.), Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital; Department of Rehabilitation (J.T.G.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Cardiology (F.E.A.U.C.), Amalia Children's Hospital; Department of Cardiology (F.M.A.H., R.N.); Department of Human Genetics (E.-J.K.); Department of Pediatrics (A.T.M.D., J.M.T.D.), Radboud Institute for Health Sciences, Amalia Children's Hospital; and Department of Internal Medicine (M.C.H.J.), Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC - 09Erasmus CE4 papers · 2024
From the Department of Neurology (K.B., J.D., N.A., B.G.M.E., N.C.V.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Neurology (K.B., C.E.E.), Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital; Department of Rehabilitation (J.T.G.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Cardiology (F.E.A.U.C.), Amalia Children's Hospital; Department of Cardiology (F.M.A.H., R.N.); Department of Human Genetics (E.-J.K.); Department of Pediatrics (A.T.M.D., J.M.T.D.), Radboud Institute for Health Sciences, Amalia Children's Hospital; and Department of Internal Medicine (M.C.H.J.), Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC - 10Groothuis JT4 papers · 2024
From the Department of Neurology (K.B., J.D., N.A., B.G.M.E., N.C.V.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Neurology (K.B., C.E.E.), Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital; Department of Rehabilitation (J.T.G.), Donders Institute for Brain, Cognition and Behaviour; Department of Pediatric Cardiology (F.E.A.U.C.), Amalia Children's Hospital; Department of Cardiology (F.M.A.H., R.N.); Department of Human Genetics (E.-J.K.); Department of Pediatrics (A.T.M.D., J.M.T.D.), Radboud Institute for Health Sciences, Amalia Children's Hospital; and Department of Internal Medicine (M.C.H.J.), Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 7 observational studies did — shown below because natural-history and cohort work can be an important step toward a trial. 7 trials are registered for congenital muscular dystrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
7 interventional trials matched congenital muscular dystrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: congenital muscular dystrophy
7
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05982119·RECRUITING·Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Conditions: Duchenne Muscular Dystrophy · Fascioscapulohumeral Muscular Dystrophy · Myotonic Dystrophy 1 · Charcot-Marie-Tooth·Matched via name phrase
- NCT05394506·RECRUITING·Modifying Factors in Striated Muscle Laminopathies
Conditions: Laminopathies · Emery Dreifuss Muscular Dystrophy 2 · LMNA-Related Congenital Muscular Dystrophy · Dilated Cardiomyopathy-1A·Matched via name phrase
Observational and natural-history studies
7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07125040·RECRUITING·Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers
Conditions: LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) · LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\) · Merosin Deficient CMD (Full or Partial) · Merosin Deficient Congenital Muscular Dystrophy·Matched via name phrase
- NCT07745218·RECRUITING·Preclinical Assessment of an Engineered HMGB1 Protein as a Novel Companion Therapy for Muscular Dystrophies
Conditions: LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)·Matched via name phrase
- NCT06924125·RECRUITING·Spanish Natural History Study for LAMA2 Muscular Dystrophy
Conditions: LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) · Merosin Deficient CMD (Full or Partial) · Merosin Deficient Congenital Muscular Dystrophy · Muscular Dystrophies·Matched via name phrase
- NCT06503367·RECRUITING·Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy
Conditions: LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Laminin subunit alpha 2-related congenital muscular dystrophy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Laminin subunit alpha 2-related congenital muscular dystrophy" OR "CMD1A" OR "Congenital muscular dystrophy due to laminin alpha2 deficiency" OR "Congenital muscular dystrophy type 1A" OR "MDC1A" OR "Merosin-negative congenital muscular dystrophy" OR "LAMA2 congenital muscular dystrophy" OR "congenital merosin-deficient muscular dystrophy type 1A" OR "congenital muscular dystrophy caused by mutation in LAMA2" OR "merosin-deficient congenital muscular dystrophy type 1A" OR "muscular dystrophy, congenital merosin-deficient, type 1A" OR "muscular dystrophy, congenital, merosin deficient or partially deficient") OR ("LAMA2" OR "LAMA2 syndrome" OR "LAMA2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Laminin subunit alpha 2-related congenital muscular dystrophy" OR "CMD1A" OR "Congenital muscular dystrophy due to laminin alpha2 deficiency" OR "Congenital muscular dystrophy type 1A" OR "MDC1A" OR "Merosin-negative congenital muscular dystrophy" OR "LAMA2 congenital muscular dystrophy" OR "congenital merosin-deficient muscular dystrophy type 1A" OR "congenital muscular dystrophy caused by mutation in LAMA2" OR "merosin-deficient congenital muscular dystrophy type 1A" OR "muscular dystrophy, congenital merosin-deficient, type 1A" OR "muscular dystrophy, congenital, merosin deficient or partially deficient"
Study-type breakdown: 0 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"congenital muscular dystrophy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T13:06:26.792Z
